Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	CD40LG	Synonyms	CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L	Type of gene	protein-coding
Chromosome	X	Map location	Xq26.3	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	CD40 ligand

Gene symbol	E2F1	Synonyms	E2F-1, RBAP1, RBBP3, RBP3	Type of gene	protein-coding
Chromosome	20	Map location	20q11.22	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	E2F transcription factor 1

Gene symbol	TNFSF9	Synonyms	4-1BB-L, CD137L, TNLG5A	Type of gene	protein-coding
Chromosome	19	Map location	19p13.3	dbXrefs
Description	TNF superfamily member 9

GTO ID	GTC3986
Trial ID	NCT02705196
Disease	Pancreatic Cancer
Altered gene	E2F1\|CD40LG\|TNFSF9
Therapeutic/Target gene	Therapeutic gene
Therapy	DNA oncolytic virus
Treatment	LOAd703\|delolimogene mupadenorepvec
Co-treatment	gemcitabine\|nab-paclitaxel
Phase	Phase1\|Phase2
Recruitment status	Recruiting
Title	Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer
Year	2016
Country	United States
Company sponsor	Lokon Pharma AB
Other ID(s)	LOKON001

Vector information

Vector	adenovirus
Construct	Ad5/35-E2F-delta24
Vector type	novel oncolytic serotype 5/35 adenovirus
Transgene/Inserted gene	CD40L, which includes CD40-mediated tumor cell apoptosis and adaptive immune activation; and 4-1BBL, which enhances immunologic memory and expands natural killer (NK) cells.
Regulatory element	a cytomegalovirus (CMV) promoter
Viral genome modification	The gene sequence of trimerized membrane-bound (TMZ)-CD40L, alone or in combination with 4-1BBL (LOAd703), separated by a T2A peptide, was synthesized with a cytomegalovirus (CMV) promoter upstream of the 5′ gene and adenovirus-flanking regions for homologous recombination into adenoviral vectors at both ends.
Vector production method	Viruses were produced by transfection of 293 cells (ATCC), followed by expansion in A549 cells (ATCC). The virus supernatants were purified by CsCl gradient centrifugation and diluted in 20 mmol/L Tris, 25 mmol/L NaCl, and 2.5% glycerol. The viable virus titer was measured using a fluorescence-forming units (ffu) assay. The LOAd(−) is the basic LOAd virus without the CMV transgene cassette.
Additional feature	CD40L\|4-1BBL

Clinical Result

Cohort1: dose level 1

Administration route	intratumoral injection\|intravenous infusion
Dosage	LOAd703, 5E10 viral particles per treatment\|gemcitabine, 1000mg/m2\|nab-paclitaxel, 125 mg/m2
Age	Adult, Older_Adult
References	PMID: 38547893

Cohort2: dose level 2

Administration route	intratumoral injection\|intravenous infusion
Dosage	LOAd703, 1E11 viral particles per treatment\|gemcitabine, 1000mg/m2\|nab-paclitaxel, 125 mg/m2
Age	Adult, Older_Adult
References	PMID: 38547893

Cohort3: dose level 3

Administration route	intratumoral injection\|intravenous infusion
Dosage	LOAd703, 5E11 viral particles per treatment\|gemcitabine, 1000mg/m2\|nab-paclitaxel, 125 mg/m2
Age	Adult, Older_Adult
References	PMID: 38547893

Cohort4: dose level 2_atezolizumab

Administration route	intratumoral injection\|intravenous infusion
Dosage	LOAd703, 1E11 viral particles per treatment\|gemcitabine, 1000mg/m2\|nab-paclitaxel, 125 mg/m2
Age	Adult, Older_Adult
References	PMID: 38547893

Cohort5: dose level 2_atezolizumab

Administration route	intratumoral injection\|intravenous infusion
Dosage	LOAd703, E11 viral particles per treatment\|gemcitabine, 1000mg/m2\|nab-paclitaxel, 125 mg/m2
Age	Adult, Older_Adult
References	PMID: 38547893

Relationship Graph

Overview of Knowledge Graph